Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Cytosorbents Corporation (CTSO:NASDAQ), powered by AI.
Cytosorbents Corporation is currently trading at $0.40. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Cytosorbents Corporation on Alpha Lenz.
Cytosorbents Corporation's P/E ratio is -3.0.
“Cytosorbents Corporation trades at a P/E of -3.0 (undervalued) with modest ROE of -96.4%.”
Ask for details →Cytosorbents Corporation is a biotechnology company that specializes in advanced blood purification technologies designed to treat life-threatening conditions in intensive care units and other hospital settings. The company's flagship product, CytoSorb, is a hemoadsorption cartridge that removes cytokines and other inflammatory mediators from blood. This device aims to help control excessive inflammation, which is a critical factor in numerous conditions such as sepsis, cardiac surgery, and trauma. Cytosorbents operates predominantly within the healthcare and medical technology sectors, with its technologies gaining attention for their potential impact on critical care and immunotherapy. Given its focus on innovative medical solutions, the company plays a pivotal role in advancing treatment protocols and improving patient outcomes. Headquartered in Princeton, New Jersey, Cytosorbents continues to expand its reach globally, participating in various clinical trials and partnerships to enhance the adoption and efficacy of its products in modern medical practice.
“Cytosorbents Corporation trades at a P/E of -3.0 (undervalued) with modest ROE of -96.4%.”
Ask for details →Cytosorbents Corporation (ticker: CTSO) is a company listed on NASDAQ in the Healthcare sector (Medical Devices). It has approximately 149 employees. Market cap is $25M.
The current price is $0.4 with a P/E ratio of -3.03x and P/B of 4.21x.
ROE is -96.39% and operating margin is -38.42%. Annual revenue is $37M.